Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 6,860,000 shares, a decrease of 20.7% from the March 15th total of 8,650,000 shares. Currently, 5.9% of the company’s stock are short sold. Based on an average daily volume of 997,400 shares, the days-to-cover ratio is currently 6.9 days.

Immatics Trading Up 3.6 %

NASDAQ:IMTX traded up $0.15 during mid-day trading on Friday, hitting $4.26. The stock had a trading volume of 205,139 shares, compared to its average volume of 653,576. Immatics has a twelve month low of $3.30 and a twelve month high of $13.77. The company has a market capitalization of $517.80 million, a PE ratio of -6.45 and a beta of 0.85. The stock has a 50-day simple moving average of $4.48 and a two-hundred day simple moving average of $6.56.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Sell-side analysts predict that Immatics will post -0.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $16.67.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after buying an additional 2,479 shares during the last quarter. Intellectus Partners LLC acquired a new stake in Immatics during the 1st quarter worth $70,000. Guggenheim Capital LLC purchased a new stake in Immatics in the fourth quarter valued at $101,000. Finally, Forefront Analytics LLC grew its holdings in shares of Immatics by 42.3% during the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company’s stock worth $113,000 after purchasing an additional 4,731 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.